Detection of Occult Tumor Cells in Regional Lymph Nodes is Associated with Poor Survival in PN0 Non-small Cell Lung Cancer: a Meta-analysis

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2016 Apr 15

PMID 27076932

Citations 6

Authors

Zhicheng He

Yang Xia

Shaowen Tang

Yijiang Chen

Liang Chen

Affiliations

Soon will be listed here.

Abstract

Background: patients of pN0 non-small cell lung cancer (NSCLC) with occult tumor cells (OTCs) in regional lymph nodes (LNs) are reported to have controversial prognostic outcomes.

Method: We pooled pN0 NSCLC patients with OTCs in LNs and compared with those without OTCs. Patient characteristics, hazard ratios (HRs) and 95% confidence intervals (CIs) for overall survival (OS) and/or disease-free survival (DFS) were analyzed. HR greater than 1 conferred an increased hazard for patients with OTCs.

Results: Eighteen articles were finally enrolled in the meta-analysis and 15 studies provided sufficient data for extracting HRs for OS, resulting to 5 articles available for DFS analysis. The combined HRs of OS was 2.22 (95% CI, 1.87 to 2.64) and 2.4 (95% CI, 1.71 to 3.36) for analysis of DFS. The similar trend was obtained in the subgroup analyses regarding detection methods and study type. Interestingly, even in the analysis of mean numbers of LNs dissection (MLND) intraoperatively, both subgroups (LNs/Pts. <12 and ≥12) illustrated significant HRs of OS (HR: 3.13, 95% CI, 2.17 to 4.52 in LNs/Pts. <12 subgroup and HR: 2.09, 95% CI, 1.63 to 2.68 in LNs/Pts. ≥12). The combined HR of OS in this section was 2.37 (95% CI, 1.63 to 2.68). No publication bias was detected in all the meta-analysis sections. The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND.

Conclusions: The prognosis of patients with OTCs is inferior to those without OTCs in the terms of OS and DFS regardless of detection methods, study types and MLND.

Citing Articles

exploration of an endobronchial sentinel lymph node procedure in lung cancer for optimizing workflow and evaluating feasibility of novel imaging tools.

Ter Woerds D, Verhoeven R, van der Heide S, Verhagen A, Aarntzen E, van der Heijden E J Thorac Dis. 2023; 15(2):291-299.

PMID: 36910083 PMC: 9992569. DOI: 10.21037/jtd-22-984.

Sentinel Lymph Node in Non-Small Cell Lung Cancer: Assessment of Feasibility and Safety by Near-Infrared Fluorescence Imaging and Clinical Consequences.

Stasiak F, Seitlinger J, Streit A, Wollbrett C, Piccoli J, Siat J J Pers Med. 2023; 13(1).

PMID: 36675751 PMC: 9866901. DOI: 10.3390/jpm13010090.

Comparison of recurrence risk between patients with clinically node-positive and -negative stage I non-small cell lung cancer following surgery: A propensity score matching analysis.

Huang K, Chen H, Lin C, Wang B, Cheng C, Lin S Thorac Cancer. 2022; 13(13):1933-1939.

PMID: 35581675 PMC: 9250836. DOI: 10.1111/1759-7714.14462.

RGD-modified nanoliposomes containing quercetin for lung cancer targeted treatment.

Zhou X, Liu H, Zhao H, Wang T Onco Targets Ther. 2018; 11:5397-5405.

PMID: 30214245 PMC: 6128275. DOI: 10.2147/OTT.S169555.

Long-term outcomes after near-infrared sentinel lymph node mapping in non-small cell lung cancer.

Digesu C, Hachey K, Gilmore D, Khullar O, Tsukada H, Whang B J Thorac Cardiovasc Surg. 2017; 155(3):1280-1291.

PMID: 29248292 PMC: 5816699. DOI: 10.1016/j.jtcvs.2017.09.150.

References

Rusch V, Hawes D, Decker P, Martin S, Abati A, Landreneau R . Occult metastases in lymph nodes predict survival in resectable non-small-cell lung cancer: report of the ACOSOG Z0040 trial. J Clin Oncol. 2011; 29(32):4313-9. PMC: 3221530. DOI: 10.1200/JCO.2011.35.2500. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Rena O, Carsana L, Cristina S, Papalia E, Massera F, Errico L . Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance. Eur J Cardiothorac Surg. 2007; 32(6):863-7. DOI: 10.1016/j.ejcts.2007.09.014. View

Ohta Y, Oda M, Wu J, Tsunezuka Y, Hiroshi M, Nonomura A . Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? Assessment from the point of view of nodal micrometastasis. J Thorac Cardiovasc Surg. 2001; 122(5):900-6. DOI: 10.1067/mtc.2001.117626. View

Franco M, Parra E, Takagaki T, Soares F, Capelozzi V . Detection of micrometastases in pN0 non-small cell lung cancer: an alternative method combining tissue microarray and immunohistochemistry. J Bras Pneumol. 2008; 34(3):129-35. DOI: 10.1590/s1806-37132008000300002. View

Osaki T, Oyama T, Inoue M, Gu C, Kodate M, Aikawa M . Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg. 2001; 49(9):545-51. DOI: 10.1007/BF02913530. View

Goldstraw P, Crowley J, Chansky K, Giroux D, Groome P, Rami-Porta R . The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007; 2(8):706-14. DOI: 10.1097/JTO.0b013e31812f3c1a. View

Parmar M, Torri V, Stewart L . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1999; 17(24):2815-34. DOI: 10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8. View

Li J, Li Z, Yu L, Shi S, Ge L, Wu J . Gene diagnosis of micrometastases in regional lymph nodes of patients with stage I non-small cell lung cancer: impact on staging and prognosis. Clin Transl Oncol. 2013; 15(11):882-8. DOI: 10.1007/s12094-013-1017-1. View

10.

Izbicki J, Passlick B, Hosch S, Kubuschock B, Schneider C, Busch C . Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis. J Thorac Cardiovasc Surg. 1996; 112(3):623-30. DOI: 10.1016/S0022-5223(96)70044-2. View

11.

Marchevsky A, Qiao J, Krajisnik S, Mirocha J, Mckenna R . The prognostic significance of intranodal isolated tumor cells and micrometastases in patients with non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg. 2003; 126(2):551-7. DOI: 10.1016/s0022-5223(03)00123-5. View

12.

Hashimoto T, Kobayashi Y, Ishikawa Y, Tsuchiya S, Okumura S, Nakagawa K . Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases. Cancer Res. 2000; 60(22):6472-8. View

13.

Li Z, Ding Z, Luo Q, Wu C, Liao M, Zhen Y . Prognostic significance of the extent of lymph node involvement in stage II-N1 non-small cell lung cancer. Chest. 2013; 144(4):1253-1260. DOI: 10.1378/chest.13-0073. View

14.

Darling G, Allen M, Decker P, Ballman K, Malthaner R, Inculet R . Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial. Chest. 2010; 139(5):1124-1129. PMC: 3087457. DOI: 10.1378/chest.10-0859. View

15.

Dobashi K, Sugio K, Osaki T, Oka T, Yasumoto K . Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance. J Thorac Cardiovasc Surg. 1997; 114(3):339-46. DOI: 10.1016/S0022-5223(97)70178-8. View

16.

Ayabe T, Tomita M, Matsuzaki Y, Ninomiya H, Hara M, Shimizu T . Micrometastasis and expression of nm23 messenger RNA of lymph nodes from lung cancer and the postoperative clinical outcome. Ann Thorac Cardiovasc Surg. 2004; 10(3):152-9. View

17.

Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009; 339:b2700. PMC: 2714672. DOI: 10.1136/bmj.b2700. View

18.

Harden S, Tokumaru Y, Westra W, Goodman S, Ahrendt S, Yang S . Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients. Clin Cancer Res. 2003; 9(4):1370-5. View

19.

Maruyama R, Sugio K, Fukuyama Y, Hamatake M, Sakada T, Saitoh G . Evaluation of p53 alterations in occult lymph node metastases. J Surg Oncol. 2000; 73(3):143-7. DOI: 10.1002/(sici)1096-9098(200003)73:3<143::aid-jso6>3.0.co;2-b. View

20.

Zheng Z, Pan T, Li J, Chen T, Song D, Yi J . [Meta-analysis of relationship between lymph node micrometastasis and prognosis in stage I non-small cell lung cancer patients]. Ai Zheng. 2004; 23(2):185-8. View